BioSpace News Archive

Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 16/347.613

Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancer

Trinity Biotech plc (Nasdaq: TRIB) has submitted its new HIV screening product, TrinScreen™ HIV, to the World Health Organisation (WHO) for approval.

Specialty diagnostics Company Precipio, Inc., announced its audited results for 2020. The Company posted revenues of $6.1 million, an increase of $3.0 million from 2019, representing a 95% year-over-year increase.

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Asher Biotherapeutics for systems pharmacology modeling in solid tumors.

Alio Medical (“Alio”), a wearable technology company focused on enabling insights through clinical-grade real-time data, today announced that Eric Hargan will join its Board of Directors as an Observer effective March 2021.

Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Charles Winter as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC)

Biom Therapeutics, a clinical stage biotech company, announced today it has received orphan drug designation status for BIO017—which is designed to treat Angelman syndrome—from the U.S. FDA’s Office of Orphan Product Development

Gold Standard Diagnostics (GSD), a Eurofins Technologies company, today announced FDA clearance of a new B. burgdorferi IgG/IgM VlsE-OspC EIA test.